Catalog number: SBB-PP0004, 25 μg
Highly active protein complex that has been purified from human peripheral blood mononuclear cell (PBMC) . Immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer. This immunoproteasome is supplied at >95% purity and experiments should be carried out at 20S immunoproteasome concentrations between 2-5 nM. [1][2][3][4]
20S Immunoproteasome, human PBMC
The immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of alpha subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasome these subunits (ß1, ß2, ß5) are replaced by three inducible subunits: PSMB9, PSMB10, and PSMB8, (ß1i, ß2i, ß5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T-Cells. 20S Immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer. This immunoproteasome is purified from human peripheral blood mononuclear cells and is supplied at >95% purity. Cells used as starting material tested negative for hepatitis B surface antigen, antibodies to hepatitis C virus, HIV type 1 antigens, and antibodies to HIV type 1 and 2. Immunoproteasome is commonly associated with the 19S, PA28 α/ß, or the PA28γ regulatory complexes. If choosing to omit PA28 during use, 20S must be chemically activated by addition of 0.035%SDS in final assay buffers.